DelveInsight’s “B-cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the B-cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The B-cell Non-Hodgkin Lymphoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the B-cell Non-Hodgkin Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; B-cell Non-Hodgkin Lymphoma Market Insights
B-cell Non-Hodgkin Lymphoma Overview
Non-Hodgkin Lymphoma (NHL) represents a heterogeneous group of malignancies of different biology and prognosis and can be divided into aggressive (fast-growing), intermediate, or indolent (slow-growing), and can develop from either B-cells or T-cells. Lymphomas that occur after allogeneic bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas.
Some of the key facts of the B-cell Non-Hodgkin Lymphoma Market Report:
- The B-cell Non-Hodgkin Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers
- According to American cancer society, about 80,470 people (44,120 males and 36,350 females) will be diagnosed with Non-Hodgkin Lymphoma in the year 2022
- B-cell lymphomas make up most (about 85%) of the Non-Hodgkin Lymphoma cases. Among the 7MM, our estimates shows that the highest Incident population of B cell- Non-Hodgkin Lymphoma was in the United States SEER, 2020, estimated that there would be near to 77,240 new cases of NHL in 2020 in the United States
- According to a study by Gena Kanas et al. (2021), The number of incident DLBCL cases in the US is projected to increase from 29,108 to 32,443 and from 26,078 to 27,981 in WE (Western Europe) from 2020 to 2025, with a total rate of increase of 11% in the US compared to 7% in the Western Europe
- Key B-cell Non-Hodgkin Lymphoma Companies: MEI Pharma, Regeneron Pharmaceuticals, AstraZeneca, Kartos Therapeutics, Dizal Pharmaceuticals, Nordic Nanovector, Roche, Eli Lilly, Janssen, Corvus Pharmaceuticals, Rafael Pharmaceuticals, AbbVie, ADC Therapeutics, Genetech, Tessa Therapeutics, Bristol Myers Squibb, Nanjing Yoko Biomedical, Nektar Therapeutics, Loxo Oncology, Debiopharm, CarsGen Therapeutics, Angiocrine Bioscience, Bio-thera solutions, HUTCHMED, Epizyme, MEI Pharma, Mustang Bio, Autous, Scopus Biopharma, Allogene Therapeutics, TG Therapeutics, AI therapeutics, and others
- Key B-cell Non-Hodgkin Lymphoma Therapies: Zandelisib, Odronextamab, AZD4573, Navtemadlin, Golidocitinib, Betalutin, and others
Get a Free sample for the B-cell Non-Hodgkin Lymphoma Market Report –
https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-market
Key benefits of the B-cell Non-Hodgkin Lymphoma Market report:
- B-cell Non-Hodgkin Lymphoma market report covers a descriptive overview and comprehensive insight of the B-cell Non-Hodgkin Lymphoma Epidemiology and B-cell Non-Hodgkin Lymphoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The B-cell Non-Hodgkin Lymphoma market report provides insights on the current and emerging therapies.
- B-cell Non-Hodgkin Lymphoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The B-cell Non-Hodgkin Lymphoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the B-cell Non-Hodgkin Lymphoma market.
Download the report to understand which factors are driving B-cell Non-Hodgkin Lymphoma epidemiology trends @ B-cell Non-Hodgkin Lymphoma Epidemiological Insights
B-cell Non-Hodgkin Lymphoma Market
The dynamics of the B-cell Non-Hodgkin Lymphoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
B-cell Non-Hodgkin Lymphoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
B-cell Non-Hodgkin Lymphoma Epidemiology Segmentation:
The B-cell Non-Hodgkin Lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of B-cell Non-Hodgkin Lymphoma
- Prevalent Cases of B-cell Non-Hodgkin Lymphoma by severity
- Gender-specific Prevalence of B-cell Non-Hodgkin Lymphoma
- Diagnosed Cases of Episodic and Chronic B-cell Non-Hodgkin Lymphoma
B-cell Non-Hodgkin Lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the B-cell Non-Hodgkin Lymphoma market or expected to get launched during the study period. The analysis covers B-cell Non-Hodgkin Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the B-cell Non-Hodgkin Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major B-cell Non-Hodgkin Lymphoma market share @ B-cell Non-Hodgkin Lymphoma market forecast
B-cell Non-Hodgkin Lymphoma Therapies and Key Companies
- Zandelisib: MEI Pharma
- Odronextamab: Regeneron Pharmaceuticals
- AZD4573: AstraZeneca
- Navtemadlin: Kartos Therapeutics
- Golidocitinib: Dizal Pharmaceuticals
- Betalutin: Nordic Nanovector
B-cell Non-Hodgkin Lymphoma Market Drivers
- Premium-price agents with superior efficacy such as CAR-T cell therapies and kinase inhibitors are expected to dominate the Non-Hodgkin Lymphoma market
Scope of the B-cell Non-Hodgkin Lymphoma Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key B-cell Non-Hodgkin Lymphoma Companies: MEI Pharma, Regeneron Pharmaceuticals, AstraZeneca, Kartos Therapeutics, Dizal Pharmaceuticals, Nordic Nanovector, Roche, Eli Lilly, Janssen, Corvus Pharmaceuticals, Rafael Pharmaceuticals, AbbVie, ADC Therapeutics, Genetech, Tessa Therapeutics, Bristol Myers Squibb, Nanjing Yoko Biomedical, Nektar Therapeutics, Loxo Oncology, Debiopharm, CarsGen Therapeutics, Angiocrine Bioscience, Bio-thera solutions, HUTCHMED, Epizyme, MEI Pharma, Mustang Bio, Autous, Scopus Biopharma, Allogene Therapeutics, TG Therapeutics, AI therapeutics, and others
- Key B-cell Non-Hodgkin Lymphoma Therapies: Zandelisib, Odronextamab, AZD4573, Navtemadlin, Golidocitinib, Betalutin, and others, and others
- B-cell Non-Hodgkin Lymphoma Therapeutic Assessment: B-cell Non-Hodgkin Lymphoma current marketed and B-cell Non-Hodgkin Lymphoma emerging therapies
- B-cell Non-Hodgkin Lymphoma Market Dynamics: B-cell Non-Hodgkin Lymphoma market drivers and B-cell Non-Hodgkin Lymphoma market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- B-cell Non-Hodgkin Lymphoma Unmet Needs, KOL’s views, Analyst’s views, B-cell Non-Hodgkin Lymphoma Market Access and Reimbursement
B-cell Non-Hodgkin Lymphoma Market Barriers
- Currently limited treatment options available for relapsed and refractory cases in B-cell Non-Hodgkin Lymphoma
- Label expansions of current therapies in Non-Hodgkin Lymphoma subtypes
Table of Contents
1. B-cell Non-Hodgkin Lymphoma Market Report Introduction
2. Executive Summary for B-cell Non-Hodgkin Lymphoma
3. SWOT analysis of B-cell Non-Hodgkin Lymphoma
4. B-cell Non-Hodgkin Lymphoma Patient Share (%) Overview at a Glance
5. B-cell Non-Hodgkin Lymphoma Market Overview at a Glance
6. B-cell Non-Hodgkin Lymphoma Disease Background and Overview
7. B-cell Non-Hodgkin Lymphoma Epidemiology and Patient Population
8. Country-Specific Patient Population of B-cell Non-Hodgkin Lymphoma
9. B-cell Non-Hodgkin Lymphoma Current Treatment and Medical Practices
10. B-cell Non-Hodgkin Lymphoma Unmet Needs
11. B-cell Non-Hodgkin Lymphoma Emerging Therapies
12. B-cell Non-Hodgkin Lymphoma Market Outlook
13. Country-Wise B-cell Non-Hodgkin Lymphoma Market Analysis (2019–2032)
14. B-cell Non-Hodgkin Lymphoma Market Access and Reimbursement of Therapies
15. B-cell Non-Hodgkin Lymphoma Market Drivers
16. B-cell Non-Hodgkin Lymphoma Market Barriers
17. B-cell Non-Hodgkin Lymphoma Appendix
18. B-cell Non-Hodgkin Lymphoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about B-cell Non-Hodgkin Lymphoma treatment, visit @ B-cell Non-Hodgkin Lymphoma Medications
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services